Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Pfizer touts animal trial results for COVID-19 vaccine candidate

By Sean Whooley | September 9, 2020

PfizerPfizer (NYSE:PFE) announced today that its COVID-19 vaccine candidate protected against infection in preliminary non-human trials.

The vaccine, being developed in collaboration with BioNTech (NSDQ:BNTX), was tested in mouse and non-human primate models. In the non-human primate study, the BNT162b2 mRNA-based vaccine candidate protected rhesus macaques against SARS-CoV-2 infection, according to a news release.

In a viral infection model, macaques received two injections with 100 µg of the vaccine candidate and macaques that received saline control injections were challenged 55 days after the second immunization with a high viral inoculum of about 1 million plaque-forming units of SARS-CoV-2. Immunization with BNT162b2 reduced viral infection with no viral RNA detected in the lower respiratory tract of the immunized animals, while the control group demonstrated evidence of viral RNA.

Among the anti-viral effects demonstrated by the vaccine were concomitant high neutralizing antibody titers and a TH1-biased cellular response in both rhesus macaques and mice. BNT162b2 also induced potent SARS-CoV-2 neutralizing antibodies in the vaccinated macaques, plus viral antigen-specific CD4+ and CD8+ T cells.

“Collectively, these preclinical results, combined with our clinical data collected to date, continue to support the promise and validity of our mRNA-based vaccine program against SARS-CoV-2 and selection of the BNT162b2 candidate, which we believe has the potential to prevent many millions of COVID-19 cases,” Pfizer senior VP & head of vaccine R&D Kathrin Jansen said in the release. “We are encouraged by the data thus far and confident in our progress towards developing a safe and effective vaccine candidate to help address this current pandemic.”

“The data we have shared today include the characterization of our lead candidate BNT162b2, as well as key animal studies that were the basis for our clinical programs. They have enabled us to advance BNT162b2 into Phase 3 evaluation,” added BioNTech founder & CEO Dr. Ugur Sahin. “This is another development milestone for providing a safe and effective potential vaccine to the global community to help end this pandemic.”

Pfizer and BioNTech have now commenced a global (excluding China) Phase II/III safety and efficacy clinical trial for the vaccine candidate, with over 25,000 participants between 18 and 85 years old enrolled in the U.S., Argentina and Brazil. Enrollment is expected to expand to Germany, Turkey and South Africa.

The companies said in the release that they are on track to seek regulatory review for BNT162b2 as early as October 2020, with plans to supply up to 100 million doses worldwide by the end of 2020 and 1.3 billion doses by the end of 2021.

In July, the U.S. Dept. of Health and Human Services and the U.S. Defense Dept. agreed to a large-scale production and U.S. delivery deal once Pfizer’s vaccine is successfully manufactured and approved. In addition to the 100 million doses initially agreed upon, the U.S. government will be able to acquire an additional 500 million doses.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, Pfizer
 

Comments

  1. Meredith Levine says

    December 10, 2020 at 9:41 am

    Was the covid vaccine for both Pfizer and Moderna studied on animals?

    Log in to Reply
    • M says

      February 22, 2021 at 10:35 pm

      where are the references to the animal trials? where are the results published? where is the proof?

      Log in to Reply
      • Brian Buntz says

        February 22, 2021 at 11:27 pm

        At the time these results were announced, the data was published here and was being peer-reviewed:

        https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1

        Log in to Reply
  2. Tsu Dho Nimh says

    December 24, 2020 at 3:36 pm

    IT’S IN THE TEXT: “The vaccine, being developed in collaboration with BioNTech (NSDQ:BNTX), was tested in mouse and non-human primate models.”

    Log in to Reply
  3. robert mckissock says

    December 30, 2020 at 7:48 pm

    I think this article is misleading because it doesn’t address the possibility of disease enhancement and it doesn’t mention long term effects. If you are really going to do an article on the vaccine, why not give us all the information like what ingredients will be added to the vaccine when they are approved for Humans? Also it would be nice to see all the results of the testing good and bad, so we can decide for ourselves if it’s safe or not.

    Log in to Reply
  4. Paula says

    January 6, 2021 at 7:35 am

    Were the animals infected with wild coronavirus after vaccination?

    Log in to Reply
  5. katie ruiz says

    January 21, 2021 at 2:12 pm

    What were the side effects and potential longer term study results? Any deaths of non-humans that participated in the trial?

    Log in to Reply
  6. Clif says

    January 23, 2021 at 8:10 am

    It’s important to note that the “Challenge Test” wasn’t administered after vaccination. They only seem to monitor for common short-term side effects. Previous mRNA vaccine attempts failed the Challenge Test which is when the test animal is introduced to the virus itself after vaccination. In many cases they had an amplified cytokine response.

    Log in to Reply
    • Martin says

      February 1, 2021 at 4:42 pm

      Clif – Do you have a source for the reference to “Previous mRNA vaccine attempts failed the Challenge Test”? I agree with your point but want to see the evidence. Thanks.

      Log in to Reply
      • Jackie says

        March 10, 2021 at 4:55 am

        Hi Martin, this study just came on my radar. It’s from last spring and it speaks to previous mRNA vaccines that were in development for SARS-COV and MERS being scrapped due to poor outcomes in animals during challenge tests. I just read another article that mentioned that even though human and animal testing are running in tandem for the C19 vaccines (this one cited Modena), they’re finding “normal” lab rats don’t seem susceptible to the SARS-COV-2 virus and are trying to breed mice that *should* be to continue their studies with. I’m not finding a follow-up report so I don’t know where they are with that.
        https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142689/

        Log in to Reply
        • Brian Buntz says

          March 10, 2021 at 4:14 pm

          Hi Jackie,

          Humans have something called an ACE-2 receptor, which is the target for the receptor-binding domain of the SARS-CoV-2 virus. Scientists have created transgenic rodents that have this receptor. I’ve seen recent reports of preclinical testing on COVID-19 vaccine candidates involving mice. It would be interesting to know if those are transgenic.

          Log in to Reply
    • Alex says

      March 9, 2021 at 3:13 pm

      Please let us know where you are getting your information about previous MRNA trials. No data on these previous trials that failed the challenge test seems to be available on the internet. Why? I have seen it said many times that all animals in previous trials died when exposed to “wild virus” but have not been able to verify this claim because I can find no data on these trials.

      Log in to Reply
  7. Orchid says

    January 25, 2021 at 4:32 am

    Yes, more information that is also easier to understand would be nice.

    Log in to Reply
  8. Fernando Ruiz says

    January 30, 2021 at 11:13 pm

    OK.
    So, now we have 2 mega trials from Pfizer and Moderna, with 73,000 human subjects, plus 30,000,000 people already vaccinated in the US, and we still DO NOT see any major adverse effects….
    At the same time, almost 450,000 people dead in the US only from COVID 19.

    How many more people need to die to make you understand that the fake conspiracy theories are baseless and you decide to contribute to this global effort to stop the pandemic and take the shot?

    Log in to Reply
    • Alex says

      March 9, 2021 at 3:06 pm

      No major adverse effects? What are you basing that on? Please cite evidence for this claim. The VAERS database tells a different story. Have you checked it recently?

      Log in to Reply
  9. Diane says

    February 9, 2021 at 4:40 am

    There is no need to test on animals already living and feel pain when we have human stem cells. I will leave all my money to the Howard Hughes stem cell research people. It is the only ethical thing to do.

    Log in to Reply
  10. Phoebe says

    February 13, 2021 at 4:40 pm

    Molecular mimicry refers to shared peptide sequences between human proteins and pathogens, which can cause the body to have an autoimmune response (meaning the body’s immune response will attack its own cells) following exposure to a virus or to a vaccine. Molecular mimicry is already thought to be a possible cause of the great variety of diseases covid-19 causes.

    In “Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine” (Kanduc, D & Shoenfeld, Y, 2020 available online from NCBI) the authors report findings that there is a huge sharing of peptide sequences between human proteins and covid-19 spike protein. There is also large overlap between mice proteins and covid. However there are none or few similarities with several other animals commonly used in medical testing, *including macaques*!

    Macaques are therefore not a viable test population for demonstrating safety of a vaccine with regard to the risk of developing an autoimmune response/disorder following vaccination. Why are only the results of the trials in macaques reported on here and not of those in mice?

    Also I agree with Diane’s comment.

    Log in to Reply
  11. Yvonne Martinez says

    March 23, 2021 at 4:58 pm

    I also agree with Diane. Please stop testing on animals!

    Log in to Reply

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50